|Table of Contents|

Inhibitory Effect of Raddeanin A in Human Non-small Cell Lung Cancer H460 Cells(PDF)

Chinese Journal of Applied & Environmental Biology[ISSN:1006-687X/CN:51-1482/Q]

2010 05
Research Field:
Publishing date:


Inhibitory Effect of Raddeanin A in Human Non-small Cell Lung Cancer H460 Cells
GAO YarongAN JunxiaZHU QiyuLI FuMA ChaoyingWANG MingkuiTANG Yaxiong
(1School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China)
(2Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China)
Raddeanin A H460 proliferation apoptosis cell cycle

Raddeanin A, a triterpenoid saponin, was isolated from Anemone raddeana Regel and identified by solvent extraction and recrystallization. The effect of Raddeanin A on cell proliferation, apoptosis and cell cycle progression of human non-small cell lung cancer (NSCLC) H460 cancer cells and its mechanisms in this aspect were studied in this paper. The results demonstrated that Raddeanin A significantly suppressed proliferation of H460 cancer cells in a dose- and time-dependent manner which was associated with induced apoptosis and cell cycle G2-M arrest. Furthermore, Raddeanin A could inhibit Akt activation, down-regulate the expression of Bcl-2 protein, and activate the cleavage of PARP, leading to marked inhibitory effect of H460 cells. These findings suggest that Raddeanin A may be a potential usefulness for preventing and treating NSCLC. Fig 5, Ref 21


1 Cohen V, Khuri FR. Chemoprevention of lung cancer. Curr Opin Pulm Med, 2004, 10 (4): 279~283
2 Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin, 2004, 54 (3): 150~180
3 Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG. Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem, 2008, 15 (11): 1044~1071
4 Agarwal R, Deep G. Kava, a tonic for relieving the irrational development of natural preventive agents. Cancer Prev Res, 2008, 1 (6): 409~412
5 Cao P (曹沛), Wu FE (吴凤锷), Ding LS( 丁立生). Advances in the studies on the chemical constituents and biologic activities for Anemone species. Nat Prod Res & Dev (天然产物研究与开发), 2004, 16 (6): 581~584
6 Liu LS (刘力生), Xiao XH (肖显华), Zhang LD (张龙弟), Zheng RL (郑荣梁), Wu FE (吴凤锷), Zhu ZQ (朱子清). Effects of anemodeanin A on DNA, RNA and protein of tumor cells in vitro and plasma cAMP in mice. Acta Pharmacol Sin (中国药理学报), 1985, 6 (3): 192~194
7 Liao X (廖循), Li BG (李伯刚), Gao XP (高小平), Guan JF (官家发), Ding LS (丁立生), Chen YZ (陈耀祖). Bioactive triterpenoidsaponins from Anemone davidii. Chin Tradit Herb Drugs (中草药), 2001, 32 (6): 493~496
8 Peng SL (彭树林), Liao X (廖循), Wang FT (王昉彤), Ding LS (丁立生). Antitumor effect of the saponins from Anemone davidii. Nat Prod Res & Dev (天然产物研究与开发), 2001,13(5):60~62
9 Ren FZ (任风芝), Zhang XX (张雪霞), Niu GY (牛桂云), Zhang L (张丽), Shan BE (单保恩), Liu GC (刘刚叁). Active antitumor constituents from Anemone raddeana Regel. Chin Tradit Herb Drugs (中草药), 2005, 36(12): 1975~1978
10 Wang MK (王明奎), Ding LS (丁立生), Wu FE (吴凤锷). Anti-tumor activity of crude saponin from Anemone raddeana Regel. Chin J Appl Environ Biol (应用与环境生物学报), 2008, 14 (3): 378~382
11 Wang MK (王明奎), Ding LS (丁立生), Wu FE (吴凤锷). Antitumor effects of raddeanin A on S1 80, H22 and U14 cell xenografts in mice. Chin J Cancer (癌症), 2008, 27 (9): 910~913
12 Tang Y, Simoneau AR, Xie J, Shahandeh B, Zi X. Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. Cancer Prevention Res, 2008, 1 (6): 439~451
13 Tang Y, Li X, Liu Z, Simoneau AR, Xie J, Zi X. Flavokawain B, a kava chalcone, exhibits robust apoptotic mechanisms on androgen receptor-negative, hormone-refractory prostate cancer cell lines and reduces tumor growth in a preclinical model. Intern J Cancer, 2010, 127 (8): 1758~1768
14 Tang Y, Simoneau AR, Liao W, Guo Y, Hoang BH, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, Mercola D, Zi X. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Therapeutics, 2009, 8 (2): 458~468
15 Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, McQueen P, Atreya D, Xie J, Simoneau AR, Hoang BH, Zi X. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer, 2010, 9: 162. PMID: 20573255
16 Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M and Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science, 2004, 303 (5660): 1010~1014
17 Altieri DC. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem, 2004, 92 (4): 656~663
18 Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov, 2009, 8 (8): 627~644
19 Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem, 1998, 273 (50): 33533~33539
20 Senderowicz AM. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol, 2004, 16 (6): 670~678
21 Stiles BL. PI-3-K and AKT: Onto the mitochondria. Adv Drug Deliv Rev, 2009, 61 (14): 1276~1282


Last Update: 2010-10-25